Introduction {#s1}
============

Most human cells display progressive telomere shortening during cell divisions, ultimately resulting in replicative senescence or apoptosis ([@bib26]; [@bib55]). In the majority of cancer cells and in continuously dividing germ line cells, however, telomere erosion is mitigated by the action of telomerase -- a specialized ribonucleoprotein (RNP) complex minimally composed of telomerase RNA (TR) and the telomerase reverse transcriptase (TERT) enzyme. Telomere homeostasis depends on the highly regulated co-ordination of telomerase RNP assembly, trafficking, and recruitment to telomeres during the S phase of the cell cycle ([@bib71]).

While all TRs contain a short internal template for telomeric DNA repeat synthesis ([@bib23]), vertebrate TRs also possess an H/ACA box small Cajal body (CB)-specific RNA (scaRNA) domain ([@bib36]; [@bib58]) ([Figure 1A](#fig1){ref-type="fig"}) that associates with the canonical H/ACA scaRNA-binding proteins ([@bib63]), including the pseudouridine synthase dyskerin ([@bib59]) and the CB chaperone WDR79/TCAB1 ([@bib81]; [@bib82]). The H/ACA region is required for the correct trafficking, stability, and catalytically active conformation of hTR ([@bib9]; [@bib36]; [@bib58]; [@bib88]) but is considered non-functional as a pseudouridylation guide RNA ([@bib57]).

![Characterization of the hTR-RNA interactome.\
(**A**) Schematic representation of hTR sequence, domain organization and bait oligonucleotides (ODNs) used in this study. (**B**) List of top 12 high-confidence hTR interacting RNAs in VA13-hTR cells, ranked based on peak score (JAMM software) across hTR pull-downs. A full list is provided in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. Predicted interaction sites in hTR for the top 12 RNAs are shown in panel **A** (blue lines; numbers indicate the rank of the transcript as shown in **B**). Details for these predicted interactions are provided in [Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}. (**C**) Overlap between hTR-interacting RNAs identified in VA13-hTR and HeLa cells. A list of interacting partners identified in both cell lines is shown next to the Venn diagram.\
10.7554/eLife.40037.005Figure 1---source data 1.List of hTR interacting RNAs in VA13-hTR and HeLa cells, ranked based on peak scores.Full peak calling results are provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.\
10.7554/eLife.40037.006Figure 1---source data 2.Details of the predicted RNA-RNA interactions for the transcripts listed in [Figure 1B](#fig1){ref-type="fig"}.](elife-40037-fig1){#fig1}

Interestingly, while hTERT expression is silenced in most human somatic cells, hTR is broadly expressed in normal tissues ([@bib18]). In addition, hTR levels are in excess over telomerase RNP complexes in cancer cells ([@bib83]), indicating that a pool of TERT-free hTR might assemble into alternate RNP complexes both in normal and transformed cells. Indeed, role(s) independent of telomerase activity -- with as yet poorly defined mechanism(s) -- have been demonstrated for hTR in cell survival and in the regulation of apoptosis ([@bib20]; [@bib39]; [@bib50]). The cell protective function of hTR was mapped to the 3' H/ACA domain and was shown to be negatively regulated by the formation of catalytically active telomerase RNP complexes ([@bib20]).

Besides serving as flexible scaffolds for protein binding and RNP assembly, most non-coding RNA classes engage in complementarity-driven base-pairing with other RNAs or DNA ([@bib16]; [@bib74]). In addition, RNA duplex formation has also been suggested to regulate messenger RNA localization/compartmentalization ([@bib49]). In recent years, several methods for either targeted ([@bib15]; [@bib45]) or transcriptome-wide ([@bib3]; [@bib53]; [@bib62]; [@bib72]) mapping of RNA-RNA interactions have been reported, providing the first glimpses into the intricate RNA interaction network in human cells. Although transcriptome-wide methods, relying on psoralen photo-crosslinking and proximity ligation ([@bib3]; [@bib53]; [@bib72]) have provided important insights into the overall network topology of the RNA interactome, the overlap in the identified interactions using the different methods is rather limited ([@bib22]), suggesting that the current approaches might cover only a fraction of the complex cellular RNA interaction network. In addition, psoralen-based methods are also biased by the sequence- and structural features of RNA duplexes, as they preferentially detect interacting regions with staggered uridine bases on opposing strands ([@bib11]; [@bib53]).

While the protein composition ([@bib63]) and chromatin-binding sites ([@bib10]) of the telomerase RNP have been characterized in detail, virtually nothing is currently known about RNAs potentially interacting with hTR. In order to better understand the regulation of hTR metabolism and to gain insights into its extra-telomeric role(s), we mapped the RNA interactome of hTR in human cells by a targeted RNA pull-down approach ([@bib15]), and uncovered a hTR-histone 1C mRNA axis involved in the regulation of human telomere homeostasis.

Results {#s2}
=======

Mapping of the hTR-RNA interactome {#s2-1}
----------------------------------

We mapped the hTR-RNA interaction network by formaldehyde cross-linking followed by RNA antisense purification and RNA sequencing (RAP-RNA^\[FA\]^ RNA-seq) ([@bib15]; the experimental pipeline is shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Since telomerase RNP formation is expected to compete with (some of) the alternative functions of hTR ([@bib20]; [@bib83]) and can also influence hTR trafficking ([@bib79]), we used both hTR^-^/hTERT^-^ VA13 cells transiently transfected by hTR (VA13-hTR) and hTR^+^/hTERT^+^ HeLa cells for hTR antisense purification ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Control RAP-RNA^\[FA\]^ pull-down of U2 small nuclear RNA (snRNA), as well as mock pull-down from untransfected (hTR-negative) VA13 cells was carried out in parallel. RNA fragments co-purifying with hTR were identified by determining their enrichment in pull-down *vs* input samples. To build a high-confidence set of hTR interacting RNA molecules, only highly (\>4 fold) enriched, reproducibly identified peaks were considered further, resulting in 80 RNA species in VA13-hTR cells. Unfiltered peak calling results produced by the JAMM universal peak finder ([@bib33]) are provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}; the top 12 hTR interacting RNAs are shown in [Figure 1B](#fig1){ref-type="fig"}, while the full list is provided as [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.

As expected, the stringent filtering criteria resulted in fewer hTR-interacting RNAs in the TERT^+^ HeLa cells (16 RNA species ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}), out of which 11 were also enriched in pull-downs from VA13-hTR cells; [Figure 1C](#fig1){ref-type="fig"}), in agreement with a possible competition between active telomerase RNP formation and non-canonical interactions ([@bib20]).

Although RAP-RNA^\[FA\]^ can detect both indirect interactions and direct RNA-RNA interactions caged or flanked by proteins ([@bib15]), prediction of potential duplex formation between hTR and the enriched RNA regions -- compared to either the corresponding antisense or shuffled RNA sequences -- suggested that the majority of the interactions are mediated by direct RNA-RNA base pairing ([Figure 2A](#fig2){ref-type="fig"}). Interestingly, the predicted interaction sites fall mostly within regions of hTR that are not thought to be involved in the regulation of telomerase activity or trafficking ([Figure 2B](#fig2){ref-type="fig"}; indicated in grey in [Figure 1A](#fig1){ref-type="fig"}), suggesting that these sequences might function as 'hubs' for RNA-RNA interactions.

![Predicted direct hTR-RNA interactions.\
(**A**) Prediction of duplex formation energies between hTR and RNA sequences enriched in hTR pull-downs in VA13-hTR cells. Antisense and randomly shuffled (5/each RNA) sequences were used as controls representing non-interacting sequences. Statistical analysis was carried out using the Mann-Whitney U test. (**B**) Circos plot ([@bib46]) showing the position of predicted direct hTR-RNA interactions. Only interactions with predicted duplex formation energies at least one standard deviation below the median of shuffled sequences were included on the plot, corresponding to 58 RNAs (72.5%) out of the 80 RNAs. The left side of the plot corresponds to the hTR sequence (with the position of the template and TRIAGE regions indicated), while the right side represents the genomic position of hTR-RNA interactors.](elife-40037-fig2){#fig2}

Confirming the validity of our approach, the stringently filtered dataset included *HSP90AB1*, the only hTR-interacting mRNA identified by the transcriptome-wide LIGR-seq method ([@bib72]). Furthermore, enrichment of selected candidates, such as *TPT1*, *FLNA*, and *IFITM3* was successfully verified by qRT-PCR on RAP samples ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

*HIST1H1C* RNA specifically interacts with hTR {#s2-2}
----------------------------------------------

We identified the *HIST1H1C* transcript, coding for the H1.2 linker histone subtype, as one of the most highly enriched RNAs upon hTR pull-down both in VA13-hTR and HeLa cells. Cell-cycle-regulated histone transcripts are processed in histone locus bodies (HLBs), nuclear structures formed at the sites of histone gene transcription and concentrating factors involved in histone pre-mRNA recognition and maturation ([@bib65]). Although HLBs are highly dynamic in space and time, they generally co-localize with CBs, operationally defined as coilin-positive nuclear foci ([@bib6]; [@bib54]; [@bib65]). Interestingly, hTR has also been shown to accumulate in CBs throughout the cell cycle ([@bib36]; [@bib88]), and to be recruited to telomeres specifically in S phase ([@bib37]; [@bib78]).

Based on their shared subnuclear localization, cell-cycle-specific regulation, and the specific, high enrichment of *HIST1H1C* in hTR pull-down samples ([Figure 3A and B](#fig3){ref-type="fig"}), we decided to characterize the *HIST1H1C*-hTR interaction and its potential functional consequences in detail. Prediction of potential base-pairing between *HIST1H1C* and hTR identified a 15-nt long region in the open reading frame (ORF) of *HIST1H1C* (nts 334--348) complementary to the terminal stem-loop sequence of the P6b region of hTR ([Figure 3C](#fig3){ref-type="fig"}), suggesting a direct RNA-RNA interaction between the two RNAs. We named this 15-nt long region TRIAGE, for [t]{.ul}elomerase [R]{.ul}NA [i]{.ul}nter[a]{.ul}cting [g]{.ul}enetic [e]{.ul}lement. The recently published cryo-EM structure of human telomerase RNP ([@bib63]) indicated that the P6b region is exposed and accessible in the holoenzyme.

![*HIST1H1C* RNA specifically interacts with hTR.\
(**A**) UCSC genome browser view showing coverage of RAP-RNA^\[FA\]^ RNA-seq over the entire HIST1 gene cluster on chromosome 6 (y axis indicates reads per million). VA13: mock-transfected VA13 cells; VA13-hTR: U1-hTR transfected VA13 cells; pd: pull-down. The position of the *HIST1H1C* and *HIST1H1B* genes and their maximum enrichment upon hTR pull-down is shown. (**B**) Blow-up of the *HIST1H1C* region, showing specific enrichment upon hTR pull-down. Control pull-downs \[for U2 snRNA (U2 pd) and hTR pull-down without formaldehyde cross-linking (non-XL)\] are also shown. (**C**) Predicted base-pairing between the TRIAGE sequence and the P6b stem-loop of hTR. The conservation of the TRIAGE sequence in the five replication-dependent somatic linker histone subtypes (*HIST1H1A-E*) is shown below. (**D**) Mutations were introduced into hTR (as shown at the bottom), disrupting complementarity with TRIAGE (SW: swap mutant; RS: rescue mutant). Relative expression levels of hTR variants (uppermost panel) and pull-down efficiencies of various transcripts (all other panels) were measured by qRT-PCR upon transient transfections of VA13 cells with the indicated hTR variants and RAP-RNA^\[FA\]^ using hTR-specific antisense oligonucleotides. The results demonstrate the specific pull-down of *HIST1H1C* by wild-type hTR. *HIST1H4D* and ribosomal RNA were used as negative controls. nd: not detectable. The positions of the regions amplified for *HIST1H1C* are illustrated in panel **B**. Error bars represent s.d. Representative results from two biological replicates, measured in triplicates, are shown. Paired two-tailed *t*-tests, \*\*\*p\<0.001.](elife-40037-fig3){#fig3}

In order to verify this RNA-RNA interaction, various mutations disrupting the TRIAGE-P6b complementarity were introduced in hTR ([Figure 3D](#fig3){ref-type="fig"}). For the ΔP6b variant, the entire terminal stem-loop of the P6b region of hTR was deleted, while for the SW variant we swapped the opposing strands of the terminal stem structure ([Figure 3D](#fig3){ref-type="fig"}). The RS ('rescue') variant of hTR was designed to disrupt base-pairing with the TRIAGE sequence while introducing complementarity to another region of *HIST1H1C* (nts 91--106; shown in [Figure 3B](#fig3){ref-type="fig"}). All hTR variants could be expressed in VA13 cells at levels similar to wt hTR ([Figure 3D](#fig3){ref-type="fig"} uppermost panel), and all could be purified by RAP-RNA^\[FA\]^ with similar efficiencies ([Figure 3D](#fig3){ref-type="fig"}). Importantly, enrichment of *HIST1H1C* upon hTR pull-down was abrogated in all P6b mutants ([Figure 3D](#fig3){ref-type="fig"}), including hTR-RS, indicating that sequence complementarity is necessary but not sufficient for the specific RNA-RNA interaction between the P6b stem-loop and the *HIST1H1C* transcript. In agreement with this, *HIST1H1B* mRNA contains the exact TRIAGE sequence ([Figure 3C](#fig3){ref-type="fig"}) but was enriched upon hTR pull-down to a much lesser extent than its *HIST1H1C* paralog ([Figure 3A](#fig3){ref-type="fig"}), suggesting that features besides base complementarity (e.g. secondary structure of the mRNA, specific protein binding *etc*.) determine the interaction.

Mutations in hTR disrupting the interaction with *HIST1H1C* RNA lead to increased telomere elongation {#s2-3}
-----------------------------------------------------------------------------------------------------

The TRIAGE-P6b interaction could lead to changes in the metabolism, activity, or localization of either *HIST1H1C* RNA or hTR. As H1.2 protein levels were not significantly affected by hTR or variant hTR expression ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), we determined whether the *HIST1H1C*-hTR interaction might play a role in the regulation of telomere homeostasis. Three independent, polyclonal HT1080 cell lines were established stably expressing each hTR variant. Endogenous hTR levels in HT1080 cells are more limiting in telomere elongation compared to other widely used cancer cell lines, enabling the characterization of mutant hTRs ([@bib13]). U1 promoter alone (pBS-U1 pr) was used as a negative control, while over-expression of wild-type hTR served as a positive control. We also included the well-characterized m1 hTR mutant (containing the G414C mutation), which fails to accumulate in CBs and causes reduced telomere lengthening in HT1080 cells ([@bib12]; [@bib36]). All hTR variants could be stably over-expressed, resulting in \~3--4 fold hTR expression over endogenous levels ([Figure 4A](#fig4){ref-type="fig"}). Telomerase activity was measured at day 32 post-transfection using the qTRAP (real-time quantitative telomeric repeat amplification protocol) assay. While deletion of the terminal stem-loop of the P6b region strongly reduced telomerase activity, hTR variants that conserved the overall RNA secondary structure (SW and RS) showed telomerase activities comparable to wild-type hTR, indicating that neither the sequence of the P6b stem-loop nor its interaction with *HIST1H1C* RNA are required for catalytically active telomerase RNP assembly ([Figure 4B](#fig4){ref-type="fig"}). This is in agreement with a previous report, where substitution of the terminal stem-loop for the GAAA tetraloop sequence showed no influence on telomerase enzymatic activity ([@bib60]). The enzymatic activity associated with hTR variants measured in cell lysates reflects the assembly of telomerase RNPs but -- owing to potential trafficking defects -- does not necessarily correlate with productive telomere elongation, as previously shown for hTR m1 ([@bib12]).

![Mutations in hTR disrupting the interaction with *HIST1H1C* RNA lead to increased telomere elongation.\
(**A**) Relative hTR expression levels and (**B**) relative telomerase activities in stably transfected polyclonal HT1080 cell lines expressing the indicated hTR variants, measured at day 32 post-transfection. Error bars represent s.d. Representative results of two-to-three biological replicates, measured in triplicates, are shown. (**C**) Cells were counted at each passage to determine average population doubling (PD) times for the HT1080 cell lines (n = 3 for each condition) stably expressing the indicated hTR variant. (**D**) Southern blot for TRF analysis at day 32 post-transfection. MTLs for the individual cell lines are indicated above the panel, while the average MTL for each hTR variant is shown by dashed lines. Statistical significance was calculated by paired two-tailed *t*-tests, \*p\<0.05, \*\*p\<0.01. Southern blots for the other time points are provided in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}. (**E**) MTL changes over time for HT1080 cells stably expressing the indicated hTR variants. Average MTL values from three independent cell lines are shown. The intercept at day 0 for the trendlines was set at the MTL of the untransfected cell population.](elife-40037-fig4){#fig4}

In order to examine whether hTR association with *HIST1H1C* RNA affects telomere maintenance, we carried out telomere restriction fragment (TRF) length analysis to follow the mean telomere length (MTL) over time in HT1080 cell lines stably expressing the hTR variants. Expression of hTR variants did not change the cell growth characteristics ([Figure 4C](#fig4){ref-type="fig"}). As expected, wild-type hTR over-expression resulted in a steady increase in MTL (averaging \~82 nt per population doubling), while U1 promoter alone, the catalytically compromised ΔP6 hTR variant or m1 hTR expression did not result in significant telomere elongation ([Figure 4D and E](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Surprisingly, cell lines over-expressing either the SW or RS variant displayed markedly increased telomere lengthening compared to wild-type hTR ([Figure 4D and E](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), suggesting that the identified *HIST1H1C*-hTR interaction might interfere with the telomeric activity of the telomerase RNP.

*HIST1H1C* regulates telomere length as a non-coding RNA {#s2-4}
--------------------------------------------------------

If the TRIAGE-P6b interaction inhibits telomere elongation, over-expression of the *HIST1H1C* transcript, independently of its coding potential, could have a negative impact on telomere length maintenance. To examine this possibility, we cloned the *HIST1H1C* coding region, flanked by an N-terminal 3xFLAG tag and the endogenous 5' and 3' regulatory sequences imparting S-phase-specific expression and polyA-independent processing ([@bib66]) into an expression vector (wtHIST1H1C). Several silent codon changes were introduced in the TRIAGE region, disrupting complementarity to the P6b stem-loop sequence of hTR ([Figure 5A](#fig5){ref-type="fig"}), but maintaining its coding potential (silentHIST1H1C). Three independent, polyclonal HT1080 cell lines were established stably expressing each HIST1H1C construct. We achieved moderate over-expression of 3xFLAG-H1.2 compared to endogenous H1.2 levels, with similar expression levels for 3xFLAG-H1.2 encoded by the wild-type HIST1H1C sequence and the silentHIST1H1C variant ([Figure 5B](#fig5){ref-type="fig"}). While cancer cells maintain a remarkable telomere length equilibrium over a long period ex vivo ([Figure 4D and E](#fig4){ref-type="fig"}), over-expression of wtHIST1H1C resulted in telomere attrition and accumulation of short telomeres in all three cell lines after 34 population doublings ([Figure 5C](#fig5){ref-type="fig"}). Importantly, silentHIST1H1C expression had no effect on the MTL ([Figure 5C](#fig5){ref-type="fig"}), demonstrating that the presence of the TRIAGE sequence is responsible for the observed phenotype, possibly regulating telomere length via the *HIST1H1C*-hTR RNA-RNA interaction, independently of H1.2 protein expression. *HIST1H1C* over-expression had no influence on telomerase enzymatic activity measured in cell lysates ([Figure 5E](#fig5){ref-type="fig"}), suggesting that the TRIAGE sequence is affecting a step following telomerase RNP assembly.

![The presence of the TRIAGE sequence in *HIST1H1C* regulates telomere length.\
(**A**) Schematic representation of HIST1H1C constructs. The TRIAGE sequence and silent mutations introduced in it are shown. FL indicates the N-terminal 3xFLAG tag. (**B**) Western blot showing 3xFLAG-H1.2 expression in stable polyclonal HT1080 cell lines. The same membrane was sequentially probed with anti-H1.2, anti-actin, and anti-FLAG antibodies. A doublet is detected with the anti-FLAG antibody, probably due to a phosphorylated H1.2 form that is not recognized by the anti-H1.2 antibody. (**C**) Southern blots for TRF analysis at days 13 (left panel) and 34 (right panel) post-transfection. MTLs for the individual cell lines are indicated above the panel, while the average MTL with the various HIST1H1C constructs is shown by dashed lines. Statistical significance was calculated by paired two-tailed *t*-tests, \*p\<0.05. (**D**) Western blot showing the loss of 3xFLAG-H1.2 expression in wtHIST1H1C-expressing polyclonal cell lines 2 and 3 (lanes 5 and 6) upon long-term culture (120 days post-transfection), and activation of the DNA damage marker p53 in cell line 1 (lane 4). (**E**) Relative telomerase activities upon transient transfection of HT1080 cells with the indicated combinations of hTR- (U1 pr and wt hTR) and histone 1C (mock, wtHIST1H1C, and silentHIST1H1C)-expressing constructs, measured 3 days post-transfection. Error bars represent s.d. Representative results of two biological replicates, measured in triplicates, are shown.](elife-40037-fig5){#fig5}

To test whether *HIST1H1C* exerts its effect via a direct RNA-RNA interaction, we carried out a rescue experiment by introducing mutations in the P6b stem-loop of hTR, restoring complementarity to the mutated TRIAGE sequence in silentHIST1H1C (P6b_sil hTR variant; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). P6b_sil hTR could be expressed both in HT1080 and VA13 cells, albeit at levels \~ 4--5 fold lower than wt hTR ([Figure 5---figure supplement 1B and C](#fig5s1){ref-type="fig"}). We attribute this difference to a potential reduction in hTR stability due to the disruption of RNA secondary structure. In addition to its defective cellular accumulation, the P6b_sil variant also lost telomerase enzymatic activity ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), similarly to the ΔP6b variant with misfolded P6b stem-loop structure.

Various combinations of hTR and *HIST1H1C* constructs -- with or without the potential to form a TRIAGE-P6b RNA duplex -- were co-transfected into VA13 cells, followed by RAP-RNA^\[FA\]^ and qRT-PCR to assess *HIST1H1C*-hTR interaction. As shown in [Figure 5---figure supplement 1C and D](#fig5s1){ref-type="fig"}, the P6b_sil variant could efficiently pull down *HIST1H1C* from silentHIST1H1C-transfected cells, but not from wtHIST1H1C-transfected cells. By digesting the PCR products, using the NciI restriction enzyme that specifically cleaves the wtHIST1H1C amplicon, we could show that wt hTR specifically interacted with wild-type *HIST1H1C*, while P6b_sil hTR only interacted with the silentHIST1H1C transcript, demonstrating a direct, complementarity-driven interaction between the two RNAs ([Figure 5---figure supplement 1D](#fig5s1){ref-type="fig"}).

Continued telomere attrition in human cells is expected to eventually result in sustained DNA damage signaling and cellular senescence ([@bib55]). Strikingly, two of the three polyclonal wtHIST1H1C-expressing cell lines, but none of the silentHIST1H1C-expressing cell lines, lost transgene expression upon long-term culture (assessed at 120 days post-transfection; [Figure 5D](#fig5){ref-type="fig"}). This strong selection pressure prevented us from reliably assessing the influence of TRIAGE-mediated telomere shortening on cell physiology in this model system, and suggested that cells without (or with very low levels of) H1.2 over-expression might possess a substantial survival advantage. In agreement with this, cell line 1 -- maintaining wild-type H1.2 over-expression ([Figure 5D](#fig5){ref-type="fig"}, lane 4) -- exhibited increased p53 protein levels, indicative of DNA damage response activation in this cell population.

To investigate the long-term consequences of *HIST1H1C* RNA over-expression on telomere homeostasis and cell physiology, we followed two complementary strategies. First, we generated 24 clonal HT1080 cell lines stably expressing the wtHIST1H1C construct. Although most clones expressed detectable levels of 3xFLAG-H1.2 protein ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}), only 12 out of 24 clones showed \>20% upregulation in their *HIST1H1C* RNA levels ([Figure 6A](#fig6){ref-type="fig"}) relative to the baseline expression measured in mock-transfected cells.

![Long-term *HIST1H1C* mRNA over-expression results in shorter telomere length and increased cellular senescence.\
(**A**) *HIST1H1C* mRNA over-expression levels relative to mock-transfected cells in clonal HT1080 cell lines stably transfected with wtHIST1H1C, measured by qRT-PCR at 10 weeks post-transfection. Values were normalized to *HIST1H3B* RNA levels. Cell lines were divided into two groups, each comprising 12 members: clones with \<20% over-expression relative to mock (in black; 'HIST1H1C baseline' group) and clones with \>20% over-expression (in red and orange; 'HIST1H1C high' group). Clone G5, showing the highest *HIST1H1C* RNA expression levels, is emphasized by orange colour. The same colour code is applied throughout panels B-E and in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}. Error bars represent s.d., n = 2, with triplicates each. (**B**) Telomere length of clonal HT1080 cell lines was assessed by the TeSLA method ([@bib48]) at 10 weeks post-transfection. Cumulative telomere frequency (calculated as the ratio of telomeres below a certain length) is shown for the individual clonal cell lines (thin dashed lines) and for the mean of the 'HIST1H1C baseline' and 'HIST1H1C high' groups (thick lines). TeSLA blots and the associated telomere length values for the individual clones are provided in [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}. (**C**) Elevated *HIST1H1C* mRNA expression levels correlate with lower mean telomere length values (left panel) and with an increase in the ratio of short telomeres (arbitrarily defined as telomeres below 1.6 kb; right panel). Each data point corresponds to a clonal HT1080 cell line stably expressing wtHIST1H1C. Statistical significance was calculated by paired two-tailed *t*-tests, \*p\<0.05. TeSLA blots and telomere length values for the individual clones are provided in [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}. Note that telomere length measurements with the TeSLA method give shorter MTL values than the TRF method utilized in [Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}, and the absolute values obtained with these distinct methods are not directly comparable ([@bib48]). (**D**) Elevated *HIST1H1C* mRNA expression levels correlate with increased cellular senescence, as measured by β-galactosidase staining. Cellular senescence in individual HT1080 clonal cell lines stably expressing wtHIST1H1C, measured at 8 and 10 weeks post-transfection, is illustrated by the diameter of the bubbles, plotted as a function of hTR expression levels (expressed relative to the average value in the 24 clonal cell lines) and *HIST1H1C* mRNA over-expression levels (relative to mock-transfected cells). (**E**) Statistical significance between the 'HIST1H1C baseline' and 'HIST1H1C high' groups was calculated by paired two-tailed *t*-tests, \*\*p\<0.01.\
10.7554/eLife.40037.017Figure 6---source data 1.Numerical values measured for the clonal HT1080 cell lines.](elife-40037-fig6){#fig6}

To obtain more sensitive telomere length measurements, we took advantage of the recently developed Telomere Shortest Length Assay (TeSLA) method that facilitates the identification of critically shortened telomeres ([@bib48]). *HIST1H1C* over-expression in the clonal cell lines was generally associated with shorter MTL and a higher frequency of short telomeres ([Figure 6B and C](#fig6){ref-type="fig"}, red and orange lines and circles and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). In agreement with the accumulation of shorter telomeres, we observed an increase in cells undergoing cellular senescence, as measured by β-galactosidase staining at two time points (8 weeks and 10 weeks post-transfection) ([Figure 6D and E](#fig6){ref-type="fig"}, red and orange circles). Interestingly, hTR expression did not correlate with cellular senescence ([Figure 6D](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), suggesting that clonal variations in hTR levels are not limiting for the maintenance of the shortest telomeres in this setting.

Secondly, we introduced a frameshift at the N-terminus of the *HIST1H1C* ORF ([Figure 7A](#fig7){ref-type="fig"}), to characterize the consequences of elevated wtHIST1H1C or silentHIST1H1C RNA expression levels without the potential confounding effects of H1.2 protein over-expression ([Figure 7B](#fig7){ref-type="fig"}). Three independent, polyclonal HT1080 cell lines were established stably expressing each frameshifted (FS) *HIST1H1C* variant. All cell lines were found to over-express *HIST1H1C* mRNA in a sustained manner ([Figure 7C](#fig7){ref-type="fig"}). Although there was no statistically significant difference in MTL between the FS_HIST1H1C and FS_silentHIST1H1C-transfected cells at 1 month post-transfection (p=0.62), by 3 months, all cell lines over-expressing FS_HIST1H1C (with wild-type TRIAGE sequence) had significantly shorter telomeres (on average by \~700 nt, p=0.011) than the FS_silentHIST1H1C-transfected controls ([Figure 7D](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}).

![*HIST1H1C* regulates telomere length acting as a non-coding RNA.\
(**A**) Schematic representation of HIST1H1C expression constructs containing a two-nucleotide frameshift achieved by insertion of two adenines following the 3xFLAG tag (FL). The frameshift results in several stop codons in the *HIST1H1C* ORF (red lines), and completely abolishes 3xFLAG-H1.2 expression, assessed by western blotting (**B**). (**C**) *HIST1H1C* mRNA expression levels in polyclonal HT1080 cell lines stably transfected with the indicated constructs were measured 3 months post-transfection by qRT-PCR. Error bars represent s.d., n = 2, with triplicates each. (**D**) Telomere length of the polyclonal HT1080 cell lines was measured by the TeSLA method at 3 months post-transfection. Cumulative telomere frequency (calculated as the ratio of telomeres below a certain length) is shown for the individual cell lines (thin dashed lines) and as average for the three biological replicates (thick lines). TeSLA blots and the associated telomere length values for the individual cell lines are provided in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}.](elife-40037-fig7){#fig7}

Taken together, our experiments with polyclonal and clonal HT1080 cell lines demonstrate a role for *HIST1H1C* RNA in telomere length homeostasis and cell survival. Since the TRIAGE-P6b interaction does not affect telomerase enzymatic activity ([Figures 4B](#fig4){ref-type="fig"} and [5E](#fig5){ref-type="fig"}), *HIST1H1C* RNA might act at a step following telomerase RNP assembly, possibly as a telomerase sponge preventing the recruitment of the enzymatically active telomerase complex to telomeres.

The hTR-RNA interactome and extra-telomeric functions of hTR {#s2-5}
------------------------------------------------------------

In addition to *HIST1H1C*, we identified a multitude of hTR-interacting RNA partners that might provide interesting new insights into the extra-telomeric function(s) of hTR. Strikingly, functional annotation analysis ([@bib31]; [@bib32]) showed that 35 out of 77 (45.5%) hTR-interacting mRNAs identified in VA13-hTR cells code for proteins involved in cytoskeleton organization and/or the regulation of apoptosis ([Figure 8](#fig8){ref-type="fig"}), thus providing a direct link -- mediated by an intricate RNA-RNA interaction network -- between hTR expression and cell survival ([@bib20]). Prominent hTR-associated mRNAs coding for apoptotic factors include the translationally controlled tumor protein (TCTP/TPT1) and filamin A (FLNA) RNAs ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), ranked sixth and first in our screen, respectively ([Figure 1B](#fig1){ref-type="fig"}). The two proteins interact with each other and are important pleiotropic regulators of DNA repair, apoptosis, tumorigenesis, and cytoskeleton organization ([@bib1]; [@bib86]). Notably, TPT1 interacts with and regulates various apoptotic factors, including Bcl-X~L~ ([@bib76]; [@bib84]) and Mcl1 ([@bib52]; [@bib85]), two regulators of the Bim apoptotic pathway, which was reported to be inhibited by hTR expression ([@bib20]).

![Functional annotation analysis of the hTR interactome.\
(**A**) Circos plot ([@bib46]) depicting hTR-interacting mRNAs coding for proteins functionally associated with cytoskeleton organization (red links and labels), apoptosis regulation (blue links and labels), or both (green links and labels). Links shown in grey correspond to RNAs not functionally associated with either cytoskeleton organization or apoptosis. The most significant gene ontology terms (GOTERM_BP_FAT, using DAVID 6.7) associated with the hTR RNA interactome are shown in (**B**).](elife-40037-fig8){#fig8}

In addition, hTR selectively interacts with a small subset of scaRNAs -- most prominently with scaRNA2 and scaRNA17 -- in both VA13-hTR and HeLa cells ([Figure 9A--C](#fig9){ref-type="fig"}). As expected for a specific interaction, the association with scaRNAs was significantly reduced with the m1 hTR variant ([@bib12]; [@bib36]) that does not accumulate in CBs ([Figure 9C](#fig9){ref-type="fig"}). By predicting base-pairing interactions between hTR and the enriched scaRNAs, we found that scaRNA2 can potentially occupy both pseudouridylation pockets of hTR, leaving an unpaired uridine exposed (U27 and U34 for the 5' and 3' pockets, respectively) ([Figure 9D](#fig9){ref-type="fig"}). This suggests the exciting possibility that hTR might behave as an active pseudouridylation guide RNA.

![hTR selectively interacts with a subset of small Cajal-body-specific non-coding RNAs.\
(**A**) Heat map showing the enrichment of small nucleolar RNAs (snoRNAs) and small Cajal body-specific RNAs (scaRNAs) upon hTR or U2 small nuclear RNA pull-down (pd). SnoRNA co-ordinates were obtained from [@bib38]. Only snoRNAs with at least 10 RNA-sequencing reads supporting their expression were included in the figure. The position of highly enriched transcripts upon hTR pull-down (scaRNA2, scaRNA17, and scarRNA12), as well as the non-enriched scaRNA11 are indicated on the right. Figure generated using Heatmapper ([@bib4]). Note that U2 is expected to interact with scaRNAs, as they mediate the modification of snRNAs. (**B**) UCSC genome browser view showing coverage of RAP-RNA^\[FA\]^ RNA-seq for selected scaRNAs. The y axis indicates reads per million. (**C**) qRT-PCR of scaRNA enrichments upon hTR pull-down from VA13 cells transiently transfected with the hTR expression constructs indicated. Error bars represent s.d. Representative results from two independent transfections, measured in triplicates, are shown. nd: not detectable. Paired two-tailed *t*-tests, \*p\<0.05, \*\*p\<0.01. (**D**) Hypothetical base-pairing between scaRNA2 and the pseudouridylation pockets of hTR. Base-pairing in the 5' pocket will require the formation of an alternative secondary structure for the 5' H/ACA hairpin of hTR ([@bib14]; [@bib77]), different from the canonical structure ([@bib7]) shown in [Figure 1A](#fig1){ref-type="fig"}.](elife-40037-fig9){#fig9}

Discussion {#s3}
==========

Using a targeted RNA pull-down approach ([@bib15]), we have identified \~80 RNA species interacting directly or indirectly with hTR. In agreement with the previously published anti-apoptotic role of hTR ([@bib20]), our dataset is highly enriched in mRNAs coding for proteins involved in the regulation of apoptosis, suggesting that (some of) the extra-telomeric functions of hTR might be mediated through RNA-RNA interactions.

Interestingly, only one of the mRNAs enriched upon hTR pull-down in our study (*HSP90AB1*) has been previously reported to interact with hTR in transcriptome-wide screens of cellular RNA-RNA interactions ([@bib3]; [@bib53]; [@bib72]). This probably reflects both the insufficient saturation of these methods ([@bib22]) and the biases resulting from psoralen photo-crosslinking ([@bib11]; [@bib53]). Indeed, many putative hTR-RNA duplexes, including the TRIAGE-P6b interaction ([Figure 3C](#fig3){ref-type="fig"}) and the predicted scaRNA2-hTR interaction ([Figure 9D](#fig9){ref-type="fig"}), do not contain uridines in a position that would conform to the substrate requirements of psoralen crosslinking. As RNA molecules have an almost unlimited potential to engage in base-pairing interactions and some species accumulate only at single-digit numbers per cell, our results -- in agreement with earlier targeted approaches ([@bib15]; [@bib45]) -- suggest that, despite major technological advances in the last decade, a large fraction of the cellular RNA interactome remains unexplored.

Interestingly, in recent years, a growing number of snoRNAs and other non-coding RNAs have been shown to be further processed to various, smaller fragments and thus regulate various cellular functions in addition to their canonical roles (e.g. [@bib16]; [@bib47]; [@bib69]). We speculate that some of the interactions identified in our study might, at least partially, reflect specific functions executed by putative, hTR-derived smaller RNA species, a possibility that remains to be addressed experimentally.

Our study identified and characterized *HIST1H1C* RNA as a negative regulator of telomere elongation through its interaction with hTR. Using a combination of hTR variants and *HIST1H1C* mutants containing either silent mutations (disrupting complementarity to hTR without interfering with H1.2 protein expression), or a frameshift at the start of the *HIST1H1C* ORF (abolishing protein production without limiting RNA expression), we demonstrated that the telomere elongation phenotype is mediated by *HIST1H1C* acting as a non-coding RNA, and not through H1.2 protein expression. As neither *HIST1H1C* over-expression, nor mutations in the P6b stem-loop of hTR disrupting *HIST1H1C* association had an effect on telomerase enzymatic activity, we propose that *HIST1H1C* regulates telomere length homeostasis acting at a step downstream of RNP assembly, possibly by sequestering the active telomerase complex and preventing its proper intranuclear targeting or recruitment to telomeres. As both hTR and replication-dependent histone (pre)mRNAs accumulate in Cajal bodies ([@bib6]; [@bib54]; [@bib36]; [@bib88]), the interaction between the two RNAs might possibly take place in these structures. Co-localization experiments between *HIST1H1C* mRNA and hTR, in different stages of the cell cycle, will have to be carried out to gain further insights into the exact mechanisms governing this regulation, which appears to substantially contribute to the exquisitely fine-tuned cellular homeostasis of telomere length maintenance.

The human genome encodes 11 histone 1 (H1) subtypes, five of which (*HIST1H1A* to *HIST1H1E*) are located -- along with a number of core histone genes -- in the large HIST1 gene cluster on chromosome 6, and are expressed in a cell cycle-dependent fashion in somatic cells ([@bib27]; [@bib29]). H1 subtypes present cell cycle, cell type, and tissue-specific differences in their expression patterns, and their relative ratios undergo profound changes during differentiation, malignant transformation, cancer progression, or under distinct physiological conditions ([@bib25]; [@bib29]; [@bib35]; [@bib67]; [@bib70]; [@bib75]). Interestingly, the TRIAGE sequence is conserved between *HIST1H1C* and *HIST1H1B*, and shows only one nucleotide difference in *HIST1H1E*, maintaining complementarity to hTR through G-U base pairing ([Figure 3C](#fig3){ref-type="fig"}). Although we observed some enrichment in hTR pull-downs for these two subtypes (and none for *HIST1H1D* with two nucleotides difference in the TRIAGE sequence), we consistently detected a preferential enrichment of *HIST1H1C* mRNA over the other variants. The reason for this specificity is currently unclear, but could potentially be explained by different intramolecular RNA secondary structures involving the TRIAGE sequence in *HIST1H1B* and *HIST1H1E*, or by the involvement of an RNA-binding protein -- preferentially associating with the *HIST1H1C* mRNA -- facilitating the TRIAGE-P6b RNA duplex formation. Nevertheless, it remains possible that under different conditions or in different cell/tissue types *HIST1H1B* and/or *HIST1H1E* might more efficiently interact with hTR and regulate its function(s).

Beyond their role in regulating chromosome condensation as structural constituents of chromatin, linker histones have been implicated in a wide variety of cellular processes (reviewed in [@bib29]), including the specific regulation of gene expression, apoptosis and the DNA damage response. Seemingly contradictory findings for H1 functions in genome stability have been reported, both for H1 histones in general and for H1.2 in particular. For example, H1.2 has been shown to repress p53-mediated transcriptional activation of target genes through -- in part -- a direct interaction with p53 ([@bib41]; [@bib64]), conferring an anti-apoptotic function upon DNA damage ([@bib64]). In contrast, the release of H1.2 from chromatin in response to DNA double-strand breaks has been shown to lead to its translocation to the cytoplasm and to result in the activation of the intrinsic apoptotic pathway and increased cell death in a Bak-dependent manner ([@bib19]; [@bib44]). Chromatin compaction states, regulated by linker histone abundance, might also influence various fundamental cellular processes, including the DNA damage response ([@bib61]; [@bib73]) and transcription from heterochromatic repeat regions ([@bib34]), potentially modulating telomere length homeostasis. Murga and co-workers reported two lines of triple knockout mouse embryonic stem cells \[TKO mES cells, lacking H1.2, H1.3 and H1.4 expression ([@bib17])\] that showed increased telomere length compared to lines expressing wild-type levels of linker histones ([@bib61]). These differences might be attributed to an ALT (alternative lengthening of telomeres)-like phenotype due to increased homologous recombination occurring in the relaxed chromatin environment caused by the drastic reduction in H1 histone expression levels ([@bib61]). Interestingly, although the sequence of the P6b stem-loop (as well as that of the TRIAGE sequence) is highly conserved in most placental mammals, mouse and rat P6b is highly divergent, suggesting that the P6b-TRIAGE interaction would not occur in these species. Whether hTR can bind to other region(s) of the rodent *Hist1h1c* mRNA (or potentially to other mouse/rat histone mRNAs) remains to be determined. Alternatively, the potential lack of this interaction might reflect divergent evolutionary strategies employed by these short-lived, small species with excessively long telomeres and somatic telomerase activity ([@bib21]). In agreement with distinct telomerase trafficking regulation in human and mouse cells, mouse telomerase RNA does not accumulate in CBs, despite the presence of a canonical CAB box in its scaRNA region ([@bib80]).

Collectively, our results support a model where the *HIST1H1C* and hTR RNAs directly interact through the TRIAGE-P6b complementarity, resulting in an attenuation of telomere elongation by enzymatically active telomerase RNPs. Importantly, our findings define an entirely novel, non-coding RNA function for *HIST1H1C*, thus providing a glimpse into a vast space of unknown functions for coding RNAs ([@bib74]). Telomere length, as a major determinant of cellular lifespan, is under strict negative regulatory control by various protein factors limiting telomerase action or trimming excessively long telomeres ([@bib8]; [@bib51]). Our findings identify an additional, RNA-based regulatory mechanism serving as a potential proliferative barrier to prevent unlimited cell divisions. While telomerase is repressed in most human somatic cells, its reactivation is a hallmark of malignant transformation, occurring in the majority (\~80 -- 90%) of cancers ([@bib40]). By limiting the available pool of telomerase RNPs via sequestering hTR and hTR-containing complexes, the *HIST1H1C* RNA-hTR interaction might constitute a tumor suppressor mechanism to curb telomere elongation even after upregulation of TERT expression, and thus could contribute to the prevention of malignant transformation, for example in the adult stem cell compartment. Alternative consequences for the interaction in other telomerase-positive human cells, such as in embryonic stem cells or activated lymphocytes, might also warrant further investigation.

Modulating telomerase activity and/or telomere elongation is an attractive and actively pursued target for cancer therapeutics ([@bib2]). On the other hand, mutations in genes involved in telomere maintenance result in a list of serious conditions, collectively referred to as telomeropathies ([@bib30]). As both aberrant telomere lengthening/maintenance and aberrant telomere shortening are of considerable clinical importance, modulating the *HIST1H1C*-hTR RNA-RNA interaction -- either by inhibiting or mimicking/facilitating duplex formation -- therefore might have significant therapeutic benefits.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation                                    Source or\                     Identifiers or link                                                                                                                                                                   Additional\
  (species) or\                                                               reference                                                                                                                                                                                                            information
  resource                                                                                                                                                                                                                                                                                         
  ---------------------------- ---------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  Genetic\                     Lipofectamine\                                 Thermo Fisher Scientific       Cat\#11668019                                                                                                                                                                         
  reagent                      2000                                                                                                                                                                                                                                                                

  Cell line\                   WI38 VA13-2RA                                  Daniela Rhodes lab (Nanyang\   N/A                                                                                                                                                                                   
  (*Homo sapiens*)                                                            Technological University)                                                                                                                                                                                            

  Cell line (*Homo sapiens*)   HT1080                                         Peter Dröge lab (Nanyang\      N/A                                                                                                                                                                                   
                                                                              Technological University)                                                                                                                                                                                            

  Cell line (*Homo sapiens*)   HeLa                                           Peter Dröge lab (Nanyang\      N/A                                                                                                                                                                                   
                                                                              Technological University)                                                                                                                                                                                            

  Antibody                     Anti-Histone\                                  Abcam                          Cat\#ab181977                                                                                                                                                                         WB: 1:2000
                               H1.2 antibody \[EPR12691\]                                                                                                                                                                                                                                          

  Antibody                     Monoclonal\                                    Sigma-Aldrich                  Cat\#F1804; RRID:[AB_262044](https://scicrunch.org/resolver/AB_262044)                                                                                                                WB: 1:1500
                               anti-FLAG M2\                                                                                                                                                                                                                                                       
                               antibody                                                                                                                                                                                                                                                            

  Antibody                     Anti-p53 (DO-1) antibody                       Santa Cruz Biotechnology       Cat\#sc126;\                                                                                                                                                                          WB: 1:1000
                                                                                                             RRID: [AB_628082](https://scicrunch.org/resolver/AB_628082)                                                                                                                           

  Antibody                     Mouse Monoclonal Anti-beta-\                   Sigma-Aldrich                  Cat\# A2228, RRID:[AB_476697](https://scicrunch.org/resolver/AB_476697)                                                                                                               WB: 1:5000
                               Actin                                                                                                                                                                                                                                                               

  Antibody                     Goat Polyclonal Anti-Mouse                     Dako                           Cat\# P0447, RRID:[AB_2617137](https://scicrunch.org/resolver/AB_2617137)                                                                                                             WB: 1:10000

  Antibody                     Goat Polyclonal Anti-Rabbit                    Dako                           Cat\# P0448, RRID:[AB_2617138](https://scicrunch.org/resolver/AB_2617138)                                                                                                             WB: 1:10000

  Recombinant DNA reagent      pU1-hTR(451)                                   This paper                     N/A                                                                                                                                                                                   

  Recombinant DNA reagent      pBS-U1-hTR                                     [@bib13]                       N/A                                                                                                                                                                                   

  Recombinant DNA reagent      pBS-U1-hTR-puro                                This paper                     N/A                                                                                                                                                                                   

  Recombinant DNA reagent      pPGK-puro-3xFLAG-wtHIST1H1C                    This paper                     N/A                                                                                                                                                                                   

  Recombinant DNA reagent      pPGK-puro-3xFLAG-silentHIST1H1C                This paper                     N/A                                                                                                                                                                                   

  Sequence-\                   NEBNext Multiplex\                             New England Biolabs            Cat\#E7335S                                                                                                                                                                           
  based reagent                Oligos for Illumina\                                                                                                                                                                                                                                                
                               (Index Primers Set 1)                                                                                                                                                                                                                                               

  Commercial\                  TeloTAGGG Telomere\                            Roche                          Cat\#12209136001                                                                                                                                                                      
  assay or kit                 Length Assay kit                                                                                                                                                                                                                                                    

  Commercial\                  DNeasy Blood and Tissue Kit                    Qiagen                         Cat\#69506                                                                                                                                                                            
  assay or kit                                                                                                                                                                                                                                                                                     

  Commercial\                  Senescence β-Galactosidase\                    Cell Signaling\                Cat\#9860                                                                                                                                                                             
  assay or kit                 Staining Kit                                   Technology                                                                                                                                                                                                           

  Commercial\                  QuantiNova SYBR\                               Qiagen                         Cat\#208154                                                                                                                                                                           
  assay or kit                 Green RT-PCR Kit                                                                                                                                                                                                                                                    

  Commercial\                  ThermoScript RT-PCR System                     Thermo\                        Cat\#11146--024                                                                                                                                                                       
  assay or kit                                                                Fisher Scientific                                                                                                                                                                                                    

  Commercial\                  Mycoplasma PCR Detection Kit                   Applied Biological Materials   Cat\#G238                                                                                                                                                                             
  assay or kit                                                                                                                                                                                                                                                                                     

  Commercial\                  Qubit dsDNA\                                   Thermo Fisher Scientific       Cat\#Q32851                                                                                                                                                                           
  assay or kit                 HS Assay Kit                                                                                                                                                                                                                                                        

  Chemical\                    Etoposide                                      Sigma-Aldrich                  Cat\#E1383                                                                                                                                                                            
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    Pierce 16% Formaldehyde (w/v), Methanol-free   Thermo Fisher Scientific       Cat\#28906                                                                                                                                                                            
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    Bovine albumin fraction V                      Thermo\                        Cat\#15260037                                                                                                                                                                         
  compound, drug                                                              Fisher\                                                                                                                                                                                                              
                                                                              Scientific                                                                                                                                                                                                           

  Chemical\                    Trizol reagent                                 Thermo Fisher Scientific       Cat\#15596026                                                                                                                                                                         
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    Dynabeads\                                     Thermo Fisher Scientific       Cat\#65001                                                                                                                                                                            
  compound, drug               MyOne Streptavidin\                                                                                                                                                                                                                                                 
                               C1                                                                                                                                                                                                                                                                  

  Chemical\                    Dynabeads MyOne Silane                         Thermo Fisher Scientific       Cat\#37002D                                                                                                                                                                           
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    Agencourt AMPure XP                            Beckman Coulter                Cat\#A63880                                                                                                                                                                           
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    Ribonuclease H                                 Thermo Fisher Scientific       Cat\#18021014                                                                                                                                                                         
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    RNase inhibitor, murine                        New England Biolabs            Cat\#M0314S                                                                                                                                                                           
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    FastAP Thermosensitive\                        Thermo Fisher Scientific       Cat\#EF0651                                                                                                                                                                           
  compound, drug               Alkaline Phosphatase                                                                                                                                                                                                                                                

  Chemical\                    T4 polynucleotide kinase                       New England Biolabs            Cat\#M0201S                                                                                                                                                                           
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    Turbo DNase                                    Thermo Fisher Scientific       Cat\#AM2239                                                                                                                                                                           
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    Exonuclease I                                  New England Biolabs            Cat\#M0293S                                                                                                                                                                           
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    RQ1 RNase-free DNase                           Promega                        Cat\#M6101                                                                                                                                                                            
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    ExoSAP-IT PCR Product Cleanup Reagent          Thermo Fisher Scientific       Cat\#78200.200 .UL                                                                                                                                                                    
  compound, drug                                                                                                                                                                                                                                                                                   

  Chemical\                    NEBNext Ultra II Q5 Master Mix                 New England\                   Cat\#M0544S                                                                                                                                                                           
  compound, drug                                                              Biolabs                                                                                                                                                                                                              

  Chemical\                    SYBR Green PCR Master Mix                      Thermo Fisher\                 Cat\#4364344                                                                                                                                                                          
  compound, drug                                                              Scientific                                                                                                                                                                                                           

  Chemical\                    FailSafe enzyme mix                            Lucigen                        Cat\# FSE5101K                                                                                                                                                                        
  compound, drug                                                                                                                                                                                                                                                                                   

  Software,\                   HISAT2 v2.0.3                                  [@bib42]                       <https://ccb.jhu.edu/software/hisat2/index.shtml>\                                                                                                                                    
  algorithm                                                                                                  RRID:[SCR_015530](https://scicrunch.org/resolver/SCR_015530)                                                                                                                          

  Software,\                   BamTools                                       [@bib5]                        <https://github.com/pezmaster31/bamtools>\                                                                                                                                            
  algorithm                                                                                                  RRID:[SCR_015987](https://scicrunch.org/resolver/SCR_015987)                                                                                                                          

  Software,\                   JAMM peak finder v1.0.7.5                      [@bib33]                       <https://github.com/mahmoudibrahim/JAMM>                                                                                                                                              
  algorithm                                                                                                                                                                                                                                                                                        

  Software,\                   RNAup                                          [@bib24]                       [http://rna.tbi.univie.ac.at/cgi-](http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAup.cgi)[bin/RNAWebSuite/RNAup.cgi](http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAup.cgi)   
  algorithm                                                                                                                                                                                                                                                                                        

  Software,\                   Circos                                         [@bib46]                       <http://circos.ca/>\                                                                                                                                                                  
  algorithm                                                                                                  RRID:[SCR_011798](https://scicrunch.org/resolver/SCR_011798)                                                                                                                          

  Software,\                   Heatmapper                                     [@bib4]                        <http://heatmapper.ca/>                                                                                                                                                               
  algorithm                                                                                                                                                                                                                                                                                        

  Software,\                   DAVID 6.7                                      [@bib31], [@bib32]             <https://david-d.ncifcrf.gov/>\                                                                                                                                                       
  algorithm                                                                                                  RRID:[SCR_001881](https://scicrunch.org/resolver/SCR_001881)                                                                                                                          

  Software,\                   TeSLA-QUANT                                    [@bib48]                       Available as supplementary item in [@bib48]\                                                                                                                                          
  algorithm                                                                                                                                                                                                                                                                                        

  Other                        RNA-sequencing data                            This paper                     SRP123633\                                                                                                                                                                            
                                                                                                             <https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP123633>                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Oligonucleotides {#s4-1}
----------------

Biotinylated ssODNs used for RNA pull-downs were purchased from Sigma-Aldrich. All other oligonucleotides were from Integrated DNA Technologies (IDT).

Plasmids {#s4-2}
--------

U1 promoter sequence and the 451-nt long human telomerase RNA region were amplified from HT1080 genomic DNA and assembled into the pU1-hTR(451) plasmid. Initial RAP-RNA^\[FA\]^ experiments in VA13 cells were carried out using transient pU1-hTR(451) transfections, achieving hTR expression levels comparable to endogenous amounts in HeLa cells \[we estimated hTR expression between \~700 and \~1800 molecules/cell, based on qRT-PCR measurements relative to HeLa cells \[\~1150 hTR molecules/cell ([@bib83])\]. The pBS-U1-hTR plasmid ([@bib13]) contains the U1-hTR cassette and additional downstream sequences from the TERC locus, and can yield \~4--6 fold higher hTR expression levels than pU1-hTR(451). All experiments involving hTR variants were carried out using the pBS-U1-hTR plasmid and its derivatives. Mutations were introduced in pBS-U1-hTR using standard overlap extension PCR protocols. Deleting the 451-nt hTR RNA region resulted in the pBS-U1 pr plasmid, while deleting the terminal stem-loop of the P6b region gave rise to pBS-U1-hTR-ΔP6b. Substitutions of the P6b stem-loop (pBS-U1-hTR-SW, pBS-U1-hTR-RS, and pBS-U1-hTR-P6b_sil) are shown in [Figure 3D](#fig3){ref-type="fig"} and in [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. The m1 hTR variant (G414C mutation) was originally described in [@bib36]. For stable transfections, a puromycin expression cassette was inserted in the EcoRV site of pBS-U1-hTR and its variants, resulting in pBS-U1-hTR-puro plasmids.

The HIST1H1C genome region, containing 735 nucleotides upstream of the HIST1H1C start codon, the HIST1H1C ORF, and 452 nucleotides downstream of the stop codon was amplified from HT1080 genomic DNA and inserted into the pPGK-puro plasmid. For control transfections, the HIST1H1C ORF was deleted (mock_HIST1H1C). The 3xFLAG sequence was inserted in-frame at the start codon of HIST1H1C, resulting in pPGK-puro-3xFLAG-wtHIST1H1C. Silent mutations in the TRIAGE sequence were introduced into this plasmid to generate pPGK-puro-3xFLAG-silentHIST1H1C ([Figure 5A](#fig5){ref-type="fig"}). In order to uncouple RNA and protein expression, a two-nucleotide insertion was added immediately after the 3xFLAG sequence, introducing a frameshift with several stop codons in the HIST1H1C ORF (pPGK-puro-3xFLAG-FS_HIST1H1C and pPGK-puro-3xFLAG-FS_silentHIST1H1C plasmids; [Figure 7A](#fig7){ref-type="fig"}).

All plasmid constructs were verified by sequencing.

Cell culture and transfections {#s4-3}
------------------------------

Telomerase-negative WI38 VA13-2RA ALT cells were cultured in minimum essential medium (MEM) supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 1x MEM NEAA, 10% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. HT1080 and HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM L-glutamine, 10% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. All cell culture reagents were purchased from Thermo Fisher Scientific. All cell lines used in this study were authenticated by short tandem repeat (STR) genotyping (1st BASE Human Cell Line Authentication Service, Singapore). The absence of mycoplasma contamination was routinely verified by the Mycoplasma PCR detection kit (Applied Biological Materials).

Transfections were carried out using Lipofectamine 2000 reagent (Thermo Fisher Scientific), according to the manufacturer's instructions. For the establishment of stably transfected polyclonal or clonal HT1080 cell lines, transfections were carried out using linearized plasmids, and selection with 3 μg/ml puromycin dihydrochloride (Thermo Fisher Scientific) was initiated 48 hr after transfection.

RNA antisense purification with formaldehyde cross-linking (RAP-RNA^\[FA\]^) {#s4-4}
----------------------------------------------------------------------------

We performed RAP-RNA^\[FA\]^ essentially as described in ([@bib15]) and in the detailed protocol available at <http://www.lncrna-test.caltech.edu/protocols/RAP_Complete_Protocol.pdf>, with minor modifications.

### Formaldehyde cross-linking and cell lysis {#s4-4-1}

100 million VA13 or HeLa cells were rinsed in phosphate buffered saline (PBS) and cross-linked with 2% methanol-free formaldehyde (Thermo Fisher Scientific) at 37°C for 10 min, followed by quenching with 500 mM final concentration of glycine at 37°C for 5 min. Cells were rinsed three times with ice-cold PBS and collected in ice-cold scraping buffer (1x PBS, 0.5% bovine albumin fraction V). Cell pellets were collected by centrifugation (1000 g at 4°C for 5 min), and washed again in ice-cold scraping buffer. Aliquots of cell pellets were flash frozen in liquid nitrogen and stored at −80°C until further use.

Pellets from \~20 million cells were lysed in 1 ml lysis buffer (10 mM HEPES pH 7.5, 20 mM KCl, 1.5 mM MgCl~2~, 0.5 mM EDTA, 1 mM TCEP \[tris(2-carboxyethyl)phosphine\], 0.5 mM PMSF (phenylmethylsulfonyl fluoride), and 0.1% NP-40) on ice for 10 min, followed by 20 dounces in a 2 ml glass dounce homogenizer. Nuclei were enriched by centrifugation at 4°C, 3300 g for 7 min, and resuspended in 1 ml GuSCN hybridization buffer (20 mM Tris-Cl pH 7.5, 7 mM EDTA, 3 mM EGTA, 150 mM LiCl, 1% NP-40, 0.2% N-lauroylsarcosine, 0.1% sodium deoxycholate, 3M guanidine thyocianate, and 2.5 mM TCEP). RNAs were fragmented using the Bioruptor sonication system (Diagenode) at high-intensity setting for a total of 10 min (30 s ON -- 30 s OFF) for VA13 cells and 15 min for HeLa cells, resulting in RNA fragments of \~150--300 nucleotides. Lysates were cleared by centrifugation at 4°C, 16,000 g for 10 min.

### RNA antisense purification {#s4-4-2}

Equimolar mixes of three biotinylated ssDNA ODNs (Sigma-Aldrich) were used for both hTR \[hTR_pd1 -- 5'-\[Biotin\]TCGCCCCCGAGAGACCCGCGGCTGACAGAGCCCAACTCTTCGCGGTGGCA (complementary to position 291--340 of hTR); hTR_pd2 -- 5'-\[Biotin\]CCCCGGGAGGGGCGAACGGGCCAGCAGCTGACATTTTTTGTTTGCTCTAG (complementary to position 160--209 of hTR); and hTR_pd3 -- 5'-\[Biotin\]GCGAGAAAAACAGCGCGCGGGGAGCAAAAGCACGGCGCCTACGCCCTTCT (complementary to position 59--108 of hTR)\] and U2 snRNA \[U2_pd1 -- 5'-\[Biotin\]GGGTGCACCGTTCCTGGAGGTACTGCAATACCAGGTCGATGCGTGGAGTG (complementary to position 139--188 of human U2 snRNA); U2_pd2 -- 5'-\[Biotin\]GACGGAGCAAGCTCCTATTCCATCTCCCTGCTCCAAAAATCCATTTAATA (complementary to position 89--138 of human U2 snRNA); and U2_pd3 -- 5'-\[Biotin\]TATTGTCCTCGGATAGAGGACGTATCAGATATTAAACTGATAAGAACAGA (complementary to position 39--88 of human U2 snRNA)\] pull-downs.

To diminish non-specific background, lysates from \~5 million cells were first pre-cleared with 100 μl of Dynabeads MyOne Streptavidin C1 beads (Thermo Fisher Scientific). 1% of the pre-cleared lysate was set aside for RNA sequencing or qRT-PCR as input RNA sample. 100 pmol of ssDNA ODN mix was added to the pre-cleared lysate and incubated at 37°C for 3 hr with constant shaking at 1200 rpm. 350 μl Dynabeads MyOne Streptavidin C1 beads were washed and resuspended in ¼ bead volume GuSCN hybridization buffer, added to the lysate-ssDNA probe mix, and incubated for a further 30 min at 37°C. Subsequently, beads were washed six times in 1x bead volume GuSCN wash buffer (20 mM Tris-Cl pH 7.5, 10 mM EDTA, 1% NP-40, 0.2% N-lauroylsarcosine, 0.1% sodium deoxycholate, 3M guanidine thyocianate, and 2.5 mM TCEP), with 5 min incubations at 45°C between washes. Finally, beads were washed twice in RNase H elution buffer (50 mM Tris-Cl pH 7.5, 75 mM NaCl, 3 mM MgCl~2~, 0.125% N-lauroylsarcosine, 0.025% sodium deoxycholate, and 2.5 mM TCEP), and bound RNAs were eluted by incubation at 37°C for 30 min in RNase H elution buffer containing 10U RNase H (Thermo Fisher Scientific, cat no. 18021--014).

### Reversal of cross-links and RNA purification {#s4-4-3}

RNA pull-down and input samples were incubated for 1 hr at 65°C in NLS digestion buffer (20 mM Tris-Cl pH 7.5, 10 mM EDTA, 2% N-lauroylsarcosine, 2.5 mM TCEP, 500 mM NaCl, and 250 μg proteinase K) to remove proteins and reverse the formaldehyde cross-links, followed by nucleic acid purification using Dynabeads MyOne Silane beads (Thermo Fisher Scientific). DNA was digested at 37°C for 30 min in a buffer containing 10 mM Tris-Cl pH 7.5, 1 mM MgCl~2~, 120 μM CaCl~2~, 10 mM KCl, 1 mM DTT, 0.002% Triton X-100, 40U murine RNase inhibitor (New England Biolabs), 3U FastAP Thermosensitive Alkaline Phosphatase (Thermo Fisher Scientific), 30U T4 polynucleotide kinase (New England Biolabs), 2U Turbo DNase (Thermo Fisher Scientific), and 20U Exonuclease I (New England Biolabs), followed by RNA purification using Dynabeads MyOne Silane beads.

### RNA sequencing library preparation {#s4-4-4}

20 pmol RiL-19 RNA adapter (5'-\[phosph\]rArGrArUrCrGrGrArArGrArGrCrGrUrCrGrUrG\[3ddC\]) ([@bib15]) was ligated to the purified RNAs by incubation in ligation mix \[1x T4 RNA ligase reaction 1 buffer, 9% DMSO, 1 mM ATP, 20% PEG8000 (New England Biolabs), 12U murine RNase inhibitor, and 40U T4 RNA ligase 1 (New England Biolabs)\] for 1.5 hr at room temperature, followed by RNA purification using Dynabeads MyOne Silane beads. Reverse transcription was carried out using the ThermoScript RT-PCR system (Thermo Fisher Scientific) and AR17 primer (5'- ACACGACGCTCTTCCGA) ([@bib15]), according to the manufacturer's instructions. Excess RT primers were removed by the ExoSAP-IT PCR product cleanup reagent (Thermo Fisher Scientific). Remaining ssDNA probes were removed by incubating the samples with Dynabeads MyOne Streptavidin C1 beads at 60°C for 15 min with shaking at 1200 rpm in C1 binding buffer (10 mM Tris-Cl pH 7.5, 250 mM LiCl, 20 mM EDTA, 0.1% Triton X-100). Before the second adapter ligation, RNAs were digested by incubation in 100 mM NaOH at 70°C for 10 min, followed by neutralization by acetic acid and cDNA purification using Dynabeads MyOne Silane beads. 40 pmol 3Tr3 DNA adapter (5'-\[phosph\]AGATCGGAAGAGCACACGTCTG\[3ddC\]) ([@bib15]) was ligated to the purified cDNAs by incubation in ligation mix (1x T4 RNA ligase reaction 1 buffer, 4% DMSO, 1 mM ATP, 24% PEG8000, and 50U T4 RNA ligase 1) overnight at room temperature, followed by nucleic acid purification using Dynabeads MyOne Silane beads. Samples were enriched by PCR using NEBNext Ultra II Q5 master mix (New England Biolabs) with NEBNext Multiplex Oligos for Illumina (Index Primers Set 1) (New England Biolabs). PCR conditions were as follows: 98°C for 30 s, 4 cycles of (98°C for 10 s -- 67°C for 30 s -- 72°C for 30 s), and a variable number of cycles of (98°C for 10 s -- 72°C for 30 s). Input samples required 4--6 cycles, pull-down samples 10--12 cycles, and negative controls 14--16 cycles at this stage to obtain sufficient DNA quantities for sequencing. PCR products were purified by Agencourt AMPure XP beads (Beckman Coulter), quantified using the Qubit dsDNA HS Assay kit (Thermo Fisher Scientific), and submitted for Illumina sequencing.

RNA-sequencing and bioinformatic analysis {#s4-5}
-----------------------------------------

Illumina HiSeq RNA-sequencing on multiplexed samples was carried out to obtain \~20 million 100-nt paired-end reads per sample. Adaptor sequences and low quality bases were trimmed from raw sequencing reads using cutadapt ([@bib56]). Reads were aligned to the human genome (GRCh38) using HISAT2 (v2.0.3) ([@bib42]) with default parameter settings. Bam files were filtered to remove PCR duplicates, reads derived from transcription of the hTR expression plasmid, mitochondrial transcripts, and ribosomal RNA sequences ([@bib15]). Peaks enriched in the pull-down over input samples were identified using the JAMM universal peak finder (v1.0.7.5) ([@bib33]) with the following parameters: *-m narrow -r peak*. To increase the stringency of our analysis, peaks were further filtered by requiring a minimum peak score of 50,000 (obtained using the JAMM software), a minimum 4-fold enrichment (defined as normalized reads in the pull-down sample/normalized reads in the input sample) over the peak region, and a minimum number of 20 reads supporting the peak. Regions enriched in any of the control pull-downs from hTR-negative, mock-transfected VA13 cells were excluded from further analysis. Peaks passing these filtering criteria, together with the unfiltered output files, are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Enriched transcripts were ranked based on peak scores obtained with the JAMM software ([@bib33]). Putative hTR-target RNA interactions were predicted with the RNAup software ([@bib24]). Functional annotation analysis was carried out using DAVID 6.7 ([@bib31]; [@bib32]), using all human genes as background.

qRT-PCR {#s4-6}
-------

For qRT-PCRs verifying the enrichment of selected transcripts upon hTR pull-down, RNAs were purified as described in the RAP-RNA^\[FA\]^ section. For measuring cellular RNA expression levels, total cellular RNA was extracted using Trizol reagent (Thermo Fisher Scientific) and treated by RQ1 DNase (Promega). qRT-PCR reactions were carried out using QuantiNova SYBR Green RT-PCR kit (Qiagen), according to the manufacturer's protocol. Amplification conditions were as described in [@bib87], followed by melting curve analysis using the Bio-Rad CFX96 qPCR instrument. Serial dilutions of positive samples were included on each plate for each target RNA to obtain standard curves for relative quantification.

qRT-PCR primer sequences are listed in [Table 1](#table1){ref-type="table"}.
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###### qRT-PCR primers used in this study.

  Primer name              Sequence (5' to 3')       Reference
  ------------------------ ------------------------- -----------
  hTR_fw                   GAAGAGGAACGGAGCGAGTC      [@bib83]
  hTR_rev                  ATGTGTGAGCCGAGTCCTG       [@bib83]
  GAPDH_fw                 ACAGCAACAGGGTGGTGGAC      [@bib83]
  GAPDH_rev                GACCATTGCTGGGGCTGGTG      [@bib83]
  28S_rRNA_fw              GTGTCAGAAAAGTTACCACA      [@bib68]
  28S_rRNA_rev             ATTATGCTGAGTGATATCCC      [@bib68]
  HIST1H1C(272-386)\_fw    GCACTCTGGTGCAAACGAAAG     
  HIST1H1C(272-386)\_rev   TTAGGTTTGGTTCCGCCCG       
  HIST1H1C(53-145)\_fw     CCCCTGTAAAGAAGAAGGCGG     
  HIST1H1C(53-145)\_rev    CCACAGCCTTGGTGATGAGC      
  HIST1H4D_fw              CCAAGCGTCACCGTAAGGTAT     
  HIST1H4D_rev             AAACTTTCAGCACTCCGCGA      
  HIST1H3B_fw              AGACAGCTCGGAAATCCACC      
  HIST1H3B_rev             AACGGTGAGGCTTTTTCACG      
  scaRNA2_fw               TTTAGGGAGGGAGAGCGGC       
  scaRNA2_rev              CTCACGCGTCCACTCACAC       
  scaRNA11_fw              GTCCTGGCCTATTTTTCTGCTCC   
  scaRNA11_rev             CGGCCCTCCTAAACTGAGAGG     
  scaRNA12_fw              TGGGGACTACAGATGAGATCTGA   
  scaRNA12_rev             GATCCAAGGTTGCGCTCAGG      
  TPT1_fw                  GGCCTTTTCCGCCCGC          
  TPT1_rev                 CTAGCTTAGCACGAGCCTGA      
  FLNA_fw                  CGGTGATCACTGTGGACACTA     
  FLNA_rev                 ATTCTCCACCACGTCCACATC     
  IFITM3_fw                GAGCTCTGCCCATGACCTG       
  IFITM3_rev               GCTGATACAGGACTCGGCTC      

Telomere restriction fragment analysis (TRF) {#s4-7}
--------------------------------------------

Telomere restriction fragments were analyzed using the TeloTAGGG Telomere Length Assay kit (Roche). Briefly, cells were harvested by trypsinization, washed in PBS and collected by centrifugation at 400 g for 4 min. Genomic DNA was isolated using DNeasy Blood and Tissue Kit (Qiagen), digested with HinfI and RsaI restriction enzymes (New England Biolabs) and separated by gel electrophoresis either on 0.8% agarose gels at 50V overnight in 1X TBE buffer or (to resolve elongated telomeres at later time points) on 1% megabase agarose gels (Bio-Rad) using a CHEF DRII equipment (Bio-Rad) under the following conditions: 120° field angle, 5 to 30 s switch times, 5 V/cm and 14°C for 14 hr in 1X TAE. Following the resolution of DNA fragments, DNA was transferred to a positively charged nylon membrane (Roche) by Southern blotting and hybridized with a digoxigenin-labelled telomeric probe. Membranes were exposed to X-ray film (Carestream) and developed in X-OMAT 2000 Processor (Kodak). Mean telomere lengths were calculated as described in [@bib43].

Telomere shortest length assay (TeSLA) {#s4-8}
--------------------------------------

The TeSLA procedure was carried out as described in [@bib48], with minor modifications. Oligonucleotide sequences for the ligation and amplification reactions were published in [@bib48].

Briefly, 50 ng of genomic DNA was ligated with TeSLA-T oligonucleotides and then digested with CviAII, BfaI, NdeI, and MseI restriction enzymes (New England Biolabs), followed by shrimp alkaline phosphatase (New England Biolabs) treatment. The digested DNA was ligated with double-stranded TeSLA adapters, and 30 pg of the ligated DNA was subsequently used for long-range PCR amplifications. Amplification reactions were carried out in 25 μl volume, using 2.5 units of FailSafe Enzyme Mix (Lucigen) with FailSafe buffer H and 0.25 μM primers (AP and TeSLA-TP). After the initial melt at 94°C for 2 min, 25 PCR cycles were carried out (94°C for 15 s, 60°C for 30 s, and 72°C for 15 min). Amplified PCR products were resolved on a 1.2% agarose gel at 50V overnight in 1X TBE buffer. Southern blotting and telomere signal detection was performed using the TeloTAGGG Telomere Length Assay kit (Roche), as described for the TRF assay. The TeSLA-QUANT software was used for image quantification and statistical analysis, as described in [@bib48].

Real-time quantitative telomeric repeat amplification protocol (RQ-TRAP) {#s4-9}
------------------------------------------------------------------------

Cells were trypsinized, washed once in ice-cold PBS, and resuspended at 10^6^ cells/ml in CHAPS lysis buffer containing 400 mM NaCl (10 mM Tris-Cl pH 7.5, 400 mM NaCl, 1 mM MgCl~2~, 1 mM EGTA, 0.5% 3-\[(3-cholamidopropyl)dimethylammonio\]−1-propanesulfonate (CHAPS), 10% glycerol, 1x complete protease inhibitor cocktail without EDTA (Roche), 5 mM β-mercaptoethanol), as described in [@bib12]. Following incubation for 30 min on ice, cell debris was removed by centrifugation at 4°C for 10 min at 12,000 g. The supernatant was aliquoted, flash frozen in liquid nitrogen and stored at −80°C until further use.

Protein concentration of the extracts was determined using the Bradford assay (Bio-Rad). Amplification reactions were carried out in 20 μl volume, using SYBR Green Universal Master Mix (Thermo Fisher Scientific), 1 mM EGTA, 80 ng TS primer (5'- AATCCGTCGAGCAGAGTT) ([@bib28]), 80 ng ACX primer (5'- GCGCGGCTTACCCTTACCCTTACCCTAACC) ([@bib28]), and 1 μl cell lysate (diluted to between 200 ng/μl and 0.3 ng/μl protein concentration).

Using the Bio-Rad CFX96 qPCR instrument, samples were incubated for 30 min at 30°C, for 10 min at 95°C, and amplified in 40 PCR cycles with 15 s at 95°C and 60 s at 60°C. Relative telomerase activities were determined using a standard curve from 5-fold serial dilutions of wild-type hTR-transfected HT1080 cells. Samples were also serially diluted to verify that the measurements were carried out in the linear range of the assay. qTRAP measurements were carried out in triplicates and repeated at least twice for each sample. Heat-inactivated wild-type hTR-transfected HT1080 cell lysates and CHAPS buffer were used as negative controls, verifying that the amplification products were due to telomerase activity.

Western blotting {#s4-10}
----------------

Cells were lysed by sonication in ice-cold RIPA buffer containing 1x Protease Inhibitor Cocktail (Roche). Proteins were then separated by SDS-PAGE and transferred to 0.2 µm PVDF membranes (Bio-Rad). Membranes were blocked with Superblock T20 (TBS) blocking buffer (Thermo Fisher Scientific) and probed with primary \[anti-Histone H1.2 (Abcam, ab181977, 1:2000 dilution); anti-FLAG M2 (Sigma, F1804, 1:1500 dilution), or anti-beta-actin (Sigma, A2228, 1:5000 dilution)\] and secondary \[(polyclonal goat anti-rabbit (Dako, P0448, 1:10,000 dilution) or polyclonal goat anti-mouse (Dako, P0447, 1:10,000 dilution)\] antibodies or HRP-conjugated p53 antibody (DO1 -- sc126, Santa Cruz Biotechnology, 1:1000 dilution). Reactive bands were visualized with Immobilon western chemiluminescent HRP substrate (Millipore) in a luminescence imager (LAS4000, Fujifilm).

Senescence-associated-β-galactosidase staining {#s4-11}
----------------------------------------------

Clonal HT1080 cell lines stably expressing exogenous wtHIST1H1C were seeded in 6-well plates and cultured for 4--5 days prior to staining. Cells were fixed and stained according to the manufacturer's protocol (Senescence β-Galactosidase Staining Kit, Cell Signaling \#9860). Stained cells were imaged with an inverted microscope (Olympus, CKX41) with PixeLINK colour megapixel firewire camera (PL-A662). The percentage of SA-β-gal positive cells were determined by manually counting the positive cells across four randomly selected microscope frames and then normalized to the total number of cells. Staining was performed in triplicates between 8 (1 sample) and 10 weeks (two samples) post-transfection, and cell counts were pooled for the analysis. HT1080 cells treated with 10 µM of the topoisomerase type 2 inhibitor Etoposide (Sigma) for 24 hr followed by 24 hr recovery served as positive control. Untransfected HT1080 cells served as negative control.

Statistical analyses {#s4-12}
--------------------

Statistical analyses were performed as described in the figure legend for each experiment. All data are presented as mean ± s.d., unless otherwise noted in the legends. All data shown are representative of two or more independent experiments, unless otherwise indicated.

Data availability {#s4-13}
-----------------

RNA-seq data that support the findings of this study have been deposited in the NCBI Sequence Read Archive (SRA) under the accession code SRP123633.
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###### Enriched peaks identified in hTR pull-down samples, using the JAMM universal peak finder ([@bib33]).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The RNA interactome of human telomerase RNA reveals a coding-independent role for a histone mRNA in telomere homeostasis\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by James Manley as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Thomas R Cech (Reviewer \#2); Marlene Oeffinger (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Thanks for submitting your manuscript to *eLife* for potential publication. As you read above, the paper now has been evaluated by three reviewers and I am pleased to report that they all very much support it. Indeed, they agreed that the manuscript reports an exciting and potentially very important analysis of the \"RNA interactome\" of human telomerase RNA (hTR). They were impressed by the depth and breadth of the analyses that include pull-down assays, mutational tests, overexpression experiments, telomere length measurements, and cellular senescence assays. Furthermore, the reviewers commented on the fact that the experiments are generally well-controlled, repeated a good number of times, and clearly explained.

Nevertheless, there were issues for which the reviewers felt that an amelioration would be great. I will subdivide those into one major issue, for which further experimental evidence is required, and some other issues that you may address experimentally and/or by editorial changes.

Major issue:

All experiments in which mutated RNAs are used and that are aimed at documenting biological effects of a loss of the supposed RNA-RNA interaction were done incorporating mutations in only one of the two partner RNAs. A rather standard experiment for these kinds of approaches is to also mutate both RNAs at the same time in such a way that the stipulated base-pairing interaction is re-established, albeit with the mutated sequences. Such an experiment would go a long way in supporting your claim that the phenotypes you see for the individual mutations are due to the presumed loss of RNA-RNA interaction. You could do this experiment rather easily in the way that you did the individual mutations (Figure 3E for example) to show that the two mutated RNAs do interact and can be pulled down.

As one reviewer put it: \"In the last paragraph of the subsection "*HIST1H1C* RNA specifically interacts with hTR", the authors conclude that sequence complementarity between the TRIAGE region of the histone mRNA and P6b of hTR is necessary for the interaction. However, mutating one partner in the proposed interaction (in this case, P6b of hTR) only shows that these sequences are necessary, it doesn\'t indicate that they\'re necessary *because* they base-pair with the other partner. Subsection "Disrupting the *HIST1H1C*-hTR RNA-RNA interaction leads to increased telomere elongation", and also the title of Figure 4, these words claim a causal relationship between disrupting the interaction and increased telomere length. But again, it\'s the mutation in hTR that causes both disruption of interaction and increased telomere length, and it\'s a plausible MODEL that it does so via disruption of an RNA-RNA interaction. (1) \"the TRIAGE sequence is responsible for the observed phenotype\" is a correct conclusion from the data, but (2) \"telomere length is regulated by the....RNA-RNA interaction\" was not shown, because only one partner was mutated (in this case, the TRIAGE sequence in the mRNA). \"80 RNA species interacting with hTR\" should be qualified to say \"80 RNA species interacting directly or indirectly with hTR.\"

The qualifications requested in the above paragraph would go away if the authors could perform a \"killer experiment\" to directly test for RNA-RNA base-pairing. This is the classic requirement in the RNA field: mutate sequence 1 and lose activity, mutate sequence 2 and lose activity, make the compensatory double-mutant and regain activity. The authors have set themselves up beautifully to do this experiment: in the subsection "HIST1H1C regulates telomere length as a non-coding RNA", they express a mutated mRNA \"silentHIST1HC\" with half of the TRIAGE nucleotides mutated. This mutant does not show the telomere elongation phenotype seen with the WT HIST1H1C mRNA. If they were to simultaneously mutate P6b in hTR so that it matched the sequence of silentHIST1HC, their model would predict that the double mutant would regain telomere elongation and regain pull-down.\"

10.7554/eLife.40037.029

Author response

> Major issue:
>
> \[...\] As one reviewer put it: \"In the last paragraph of the subsection "HIST1H1C RNA specifically interacts with hTR", the authors conclude that sequence complementarity between the TRIAGE region of the histone mRNA and P6b of hTR is necessary for the interaction. However, mutating one partner in the proposed interaction (in this case, P6b of hTR) only shows that these sequences are necessary, it doesn\'t indicate that they\'re necessary because they base-pair with the other partner. Subsection "Disrupting the HIST1H1C-hTR RNA-RNA interaction leads to increased telomere elongation", and also the title of Figure 4, these words claim a causal relationship between disrupting the interaction and increased telomere length. But again, it\'s the mutation in hTR that causes both disruption of interaction and increased telomere length, and it\'s a plausible MODEL that it does so via disruption of an RNA-RNA interaction. (1) \"the TRIAGE sequence is responsible for the observed phenotype\" is a correct conclusion from the data, but (2) \"telomere length is regulated by the....RNA-RNA interaction\" was not shown, because only one partner was mutated (in this case, the TRIAGE sequence in the mRNA). \"80 RNA species interacting with hTR\" should be qualified to say \"80 RNA species interacting directly or indirectly with hTR.\"
>
> The qualifications requested in the above paragraph would go away if the authors could perform a \"killer experiment\" to directly test for RNA-RNA base-pairing. This is the classic requirement in the RNA field: mutate sequence 1 and lose activity, mutate sequence 2 and lose activity, make the compensatory double-mutant and regain activity. The authors have set themselves up beautifully to do this experiment: in the subsection "HIST1H1C regulates telomere length as a non-coding RNA", they express a mutated mRNA \"silentHIST1HC\" with half of the TRIAGE nucleotides mutated. This mutant does not show the telomere elongation phenotype seen with the WT HIST1H1C mRNA. If they were to simultaneously mutate P6b in hTR so that it matched the sequence of silentHIST1HC, their model would predict that the double mutant would regain telomere elongation and regain pull-down.\"

We carried out a conceptually similar experiment, incorporating mutations in the P6b stem-loop of hTR that introduced complementarity to a region of *HIST1H1C* distinct from the TRIAGE sequence (RS mutant in Figures 3 and 4). In that case, complementarity in itself was not sufficient to 'rescue' the hTR-*HIST1H1C* association. We speculated that the *HIST1H1C* region complementary to the RS-hTR variant might not be accessible for hybridization. Alternatively, P6b-TRIAGE duplex formation might be facilitated by an RNA-binding protein with some sequence-specificity/preference.

Now, based on the reviewers' recommendations, we have introduced mutations in the P6b stem-loop of hTR that re-establish complementarity to the silentHIST1H1C mRNA. As shown in a new Figure 5---figure supplement 1, this hTR variant specifically interacts with and pulls down the silentHIST1H1C mutant mRNA, but not wtHIST1H1C. Similarly, wild-type hTR only pulled down the wild-type HIST1H1C mRNA (either endogenous or exogenous), but not the silentHIST1H1C variant. These results clearly demonstrate a direct RNA-RNA interaction between hTR and *HIST1H1C*, and confirm the requirements for the TRIAGE and P6b regions for duplex formation. Unfortunately, the mutant hTR does not support the assembly of catalytically active telomerase RNPs, possibly due to the disruption of the P6b stem-loop structure, which might also interfere with the correct folding of the adjacent P6.1 region.
